#URU URU Metals Limited – Results of shareholder analysis

URU announces that, following the completion of an independent third-party shareholder register analysis of depositary interest holdings, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the depositary interests representing the ordinary issued share capital of the Company (“Ordinary Shares”) as at 30 June 2025. […]

#ORPH Open Orphan – Appointment of Nominated Adviser and Joint Broker

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the completion of […]

#SVML Sovereign Metals – Appointment of Joint Corporate Broker

Sovereign Metals Limited (ASX:SVM; AIM:SVML) (Company or Sovereign ) is pleased to to announce the appointment of Joh. Berenberg, Gossler & Co KG (Berenberg) as the Company’s Joint Corporate Broker, for purposes of the Company’s AIM listing, with immediate effect .   Berenberg, who are based in London, will work alongside the Company’s broker Optiva Securities to further assist […]

#TYM Tertiary Minerals – Results of AGM

Tertiary Minerals plc (LON: TYM), the AIM traded mineral exploration and development company, whose focus is on energy transition and precious metals, held its Annual General Meeting (“AGM”) today and is pleased to announce that all resolutions were duly passed. The following proxy votes were received in respect of the resolutions. Votes withheld are not […]

#TYM Tertiary Minerals – Full Exercise of Broker Option

Tertiary Minerals plc (AIM: TYM), the London listed explorer focussed on energy transition and precious metals in Nevada and Zambia, is pleased to announce that, further to the Company’s announcement of a fundraising on 19 January 2022 (the “Fundraising”), the Broker Option, a facility to allow existing shareholders to participate in the Fundraising on similar […]

#POLB Poolbeg Pharma – Scientific Advisory Board Appointment

25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board . Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division […]

#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to […]

#ORPH Open Orphan – £1.5m Contract renewal for Venn Life Sciences

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with […]